Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Behrens
Bruce Behrens, Glenbrook New South Wales AU
| Patent application number | Description | Published |
|---|---|---|
| 20110259219 | A Method of Printing - The present invention relates to a method of printing on a polymeric film using a gravure printing press, a method of making rollers for a gravure printing press and a set of gravure rollers. The invention enables standardised process colours such as, CYMK colours to be combined to from non-standardised process colours such as, secondary and tertiary colours via a select range of screen angles and screen rulings. | 10-27-2011 |
Carsten Behrens, Kobenhaven N DK
Carsten Behrens, Copenhagen N DK
| Patent application number | Description | Published |
|---|---|---|
| 20090143592 | Glucagon Antagonists/Inverse Agonists - A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity. | 06-04-2009 |
| 20100028939 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest - This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes. | 02-04-2010 |
| 20100056428 | MODIFIED PROTEINS - Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins. | 03-04-2010 |
Carsten Behrens, Kobenhavn N DK
| Patent application number | Description | Published |
|---|---|---|
| 20080275066 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists - The invention provides compounds of formula (I) for use as GLP-1 receptor agonists. | 11-06-2008 |
| 20090036353 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers - Insulin conjugated with structurally well defined, bifurcated and trifurcated polymers can be use by pulmonary delivery for systemic absorption through the lungs to reduce or eliminate the need for administering other insulins by injection. | 02-05-2009 |
| 20090240028 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides - The invention provides synthesis and application of new structural well defined branched polymers as protraction agents for peptide and protein. | 09-24-2009 |
| 20110223151 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY - The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing said conjugates, to pharmaceutical compositions comprising said conjugates and to the use of the conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia. | 09-15-2011 |
Christian Behrens, Palaiseau FR
| Patent application number | Description | Published |
|---|---|---|
| 20090130094 | Cytotoxic Antibodies Directed Against Antibodies Inhibiting Factor VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A. | 05-21-2009 |
| 20090175789 | Antibody raised against the ldl receptor - The present invention relates to a monoclonal antibody raised against the human LDL (Low Density Lipoprotein) receptor, binding to the peptide corresponding to amino acids 195-222 (SEQ ID NO: 1) in the peptide sequence for the human LDL receptor; to the use thereof as a drug; to a pharmaceutical composition containing this antibody; and to the use thereof in immunohistochemical analyses of cancerous, healthy, or cirrhotic tissues, in Western-Blot or ELISA analyses, or in in vivo quantification tests. | 07-09-2009 |
| 20100098706 | MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN LDL RECEPTOR - The invention relates to a monoclonal antibody directed against the human LDL (Low Density Lipoprotein) receptor, in which the variable region of each of the light chains is coded by the murine nucleic acid sequence SEQ ID NO: 5, the variable region of each of the heavy chains is coded by the murine nucleic acid sequence SEQ ID NO: 7, or by nucleic acid sequences having a sufficient homology with the sequences SEQ ID NO: 5 and SEQ ID NO: 7 so that the nature and the affinity of the bond between the antibody and its antigene are not modified, while the constant regions of the light chains and the heavy chains thereof are constant regions from a non-murine species. | 04-22-2010 |
| 20110201033 | G IMMUNOGLOBULIN USED AGAINST ANTHRAX TOXINS - An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes: | 08-18-2011 |
| 20110274684 | CYTOTOXIC ANTIBODIES DIRECTED AGAINST ANTIBODIES INHIBITING FACTOR VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A. | 11-10-2011 |
| 20120009188 | OPTIMIZED FC VARIANTS - A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region. | 01-12-2012 |
Christian Behrens, Palaisem FR
| Patent application number | Description | Published |
|---|---|---|
| 20090263380 | ANTI-IDIOTYPIC ANTIBODIES NEUTRALIZING THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST THE C1 DOMAIN OF FACTOR VIII - The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A. | 10-22-2009 |
Christian Behrens, Bundlesland FR
| Patent application number | Description | Published |
|---|---|---|
| 20110318757 | RECOMBINANT ANTI-MUC1 ANTIBODIES - Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analyses, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes. | 12-29-2011 |
Sam Behrens, New South Wales AU
| Patent application number | Description | Published |
|---|---|---|
| 20090127976 | Method and Apparatus for Harvesting Energy from Mechanical Vibrations - A method of harvesting energy from a vibrational energy source having a varying energy characteristic. The method includes the step of varying a characteristic of a harvesting arrangement arranged to harvest the energy, the characteristic of the harvesting arrangement being varied in response to the varying energy characteristic of the vibrational energy source. | 05-21-2009 |
Tim Behrens, Valby DK
| Patent application number | Description | Published |
|---|---|---|
| 20120068469 | WIND TURBINE ROTOR BLADE - A wind turbine blade extending in a longitudinal direction from a root end to a tip end and defining an aerodynamic airfoil cross-section between a leading edge and a trailing edge in a chordwise direction transverse to the longitudinal direction, the aerodynamic airfoil cross-section having an effective camber in the chordwise direction; the wind turbine blade comprising: blade body; first device for modifying the aerodynamic surface or shape of the blade, the position and/or movement of the first device relative to the blade body being controlled by a first actuation mechanism; second device for modifying the effective camber of the airfoil cross section; herein, in use, the first device modifies the aerodynamic surface or shape of the blade at a frequency up to a first maximum frequency and the second device modifies the effective camber of the airfoil cross section at a frequency up to a second maximum frequency, the second maximum frequency being higher than the first maximum frequency. | 03-22-2012 |